TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME

被引：0

作者：

Mariette, X. ^{[1
]}

Curtis, J. ^{[2
]}

Lee, E. ^{[3
]}

Benda, B. ^{[4
]}

Kaplan, I. ^{[5
]}

Soma, K. ^{[5
]}

Kwok, K. ^{[6
]}

Geier, J. ^{[6
]}

Wang, L. ^{[5
]}

Riese, R. ^{[5
]}

机构：

[1] Univ Paris Sud, Hop Bicetre, Paris, France

[2] Univ Alabama Birmingham, Birmingham, AL USA

[3] Seoul Natl Univ, Seoul, South Korea

[4] Pfizer Inc, Collegeville, PA USA

[5] Pfizer Inc, Groton, CT 06340 USA

[6] Pfizer Inc, New York, NY USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷

关键词：

D O I：

10.1136/annrheumdis-2014-eular.2139

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0147

引用

页码：230 / 230

页数：1

共 50 条

[1] Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Curtis, Jeffrey R.
Lee, Eun Bong
Kaplan, Irina V.
Kwok, Kenneth
Geier, Jamie
Benda, Birgitta
Soma, Koshika
Wang, Lisy
Riese, Richard
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) : 831 - 841
[2] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES IN JAPANESE PATIENTS ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
Tanaka, Y.
Takeuchi, T.
Yamanaka, H.
Hirose, T.
Toyoizumi, S.
Zwillich, S.
Geier, J.
Riese, R.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 230 - 231
[3] Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
Mariette, X.
Curtis, J. R.
Lee, E. B.
Benda, B.
Kaplan, I.
Soma, K.
Chew, R.
Geier, J.
Wang, L.
Riese, R.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S340 - S340
[4] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
Marlette, X.
Curtis, J. R.
Lee, E. B.
Riese, R.
Kaplan, I.
Chew, R.
Geier, J.
Wang, L.
Bradley, J. D.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 199 - 199
[5] Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
Lee, E. B.
Curtis, J. R.
Riese, R.
Connell, C. A.
Chew, R.
Boy, M. G.
Maller, E.
Su, C.
Wang, L.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S191 - S191
[6] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF GASTROINTESTINAL ADVERSE EVENTS ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
Lee, E. B.
Curtis, J. R.
Riese, R.
Connell, C.
Chew, R.
Boy, M.
Maller, E.
Su, C.
Wang, L.
Bradley, J.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 202 - 203
[7] Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis
O'Dell, Kate M.
Rummel, Ashley E.
FORMULARY, 2012, 47 (10) : 350 - +
[8] Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Dowty, Martin E.
Jesson, Michael I.
Ghosh, Sarbani
Lee, Jamie
Meyer, Debra M.
Krishnaswami, Sriram
Kishore, Nandini
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (01): : 165 - 173
[9] The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
Hodge, J. A.
Kawabata, T. T.
Krishnaswami, S.
Clark, J. D.
Telliez, J. -B.
Dowty, M. E.
Menon, S.
Lamba, M.
Zwillich, S.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (02) : 318 - 328
[10] Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Strand, Vibeke
Kanik, Keith S.
Connell, Carol
Wilkinson, Bethanie
Gruben, David
Wallenstein, Gene
ARTHRITIS AND RHEUMATISM, 2013, 65 : S1002 - S1002

← 1 2 3 4 5 →